Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-6016a Phase I Single Ascending Dose Study in Healthy Japanese Subjects
jRCT2051200155Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in fibrodysplasia ossificans progressiva (FOP) comparing DS-6016a with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Apr 2021; status: completed.
02
Drugs
prafnosbart
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on jRCT2051200155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200155.